X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs CADILA HEALTHCARE - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD CADILA HEALTHCARE ORCHID PHARMA LTD/
CADILA HEALTHCARE
 
P/E (TTM) x 0.2 23.3 0.7% View Chart
P/BV x 0.2 5.9 3.3% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ORCHID PHARMA LTD   CADILA HEALTHCARE
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
CADILA HEALTHCARE
Mar-17
ORCHID PHARMA LTD/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs194460 42.2%   
Low Rs35305 11.5%   
Sales per share (Unadj.) Rs276.592.1 300.2%  
Earnings per share (Unadj.) Rs-79.214.8 -534.6%  
Cash flow per share (Unadj.) Rs-43.518.5 -235.1%  
Dividends per share (Unadj.) Rs03.20 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs53.968.0 79.3%  
Shares outstanding (eoy) m70.451,023.74 6.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.2 10.0%   
Avg P/E ratio x-1.425.8 -5.6%  
P/CF ratio (eoy) x-2.620.7 -12.7%  
Price / Book Value ratio x2.15.6 37.7%  
Dividend payout %021.6 0.0%   
Avg Mkt Cap Rs m8,067391,581 2.1%   
No. of employees `0002.816.9 16.6%   
Total wages/salary Rs m2,52715,002 16.8%   
Avg. sales/employee Rs Th6,956.15,594.5 124.3%   
Avg. wages/employee Rs Th902.5890.1 101.4%   
Avg. net profit/employee Rs Th-1,993.0899.9 -221.5%   
INCOME DATA
Net Sales Rs m19,47794,295 20.7%  
Other income Rs m4071,286 31.7%   
Total revenues Rs m19,88495,581 20.8%   
Gross profit Rs m1,10319,036 5.8%  
Depreciation Rs m2,5193,750 67.2%   
Interest Rs m5,227450 1,161.5%   
Profit before tax Rs m-6,23616,122 -38.7%   
Minority Interest Rs m20338 5.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-3 -17,033.3%   
Tax Rs m-1251,289 -9.7%   
Profit after tax Rs m-5,58015,168 -36.8%  
Gross profit margin %5.720.2 28.0%  
Effective tax rate %2.08.0 25.1%   
Net profit margin %-28.716.1 -178.1%  
BALANCE SHEET DATA
Current assets Rs m11,01460,223 18.3%   
Current liabilities Rs m32,06053,058 60.4%   
Net working cap to sales %-108.17.6 -1,422.1%  
Current ratio x0.31.1 30.3%  
Inventory Days Days9570 135.9%  
Debtors Days Days3488 38.1%  
Net fixed assets Rs m29,44072,984 40.3%   
Share capital Rs m7051,024 68.8%   
"Free" reserves Rs m2,04368,576 3.0%   
Net worth Rs m3,80069,600 5.5%   
Long term debt Rs m9,01824,684 36.5%   
Total assets Rs m46,510152,207 30.6%  
Interest coverage x-0.236.8 -0.5%   
Debt to equity ratio x2.40.4 669.2%  
Sales to assets ratio x0.40.6 67.6%   
Return on assets %-0.810.3 -7.4%  
Return on equity %-146.921.8 -673.9%  
Return on capital %-3.717.9 -20.8%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51321,280 35.3%   
Fx outflow Rs m5,64910,874 51.9%   
Net fx Rs m1,86510,406 17.9%   
CASH FLOW
From Operations Rs m1,68213,495 12.5%  
From Investments Rs m-9,860-29,103 33.9%  
From Financial Activity Rs m6,64423,158 28.7%  
Net Cashflow Rs m-1,5357,556 -20.3%  

Share Holding

Indian Promoters % 32.3 74.8 43.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 8.3 55.4%  
FIIs % 3.3 5.9 55.9%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 11.0 502.7%  
Shareholders   84,811 44,069 192.5%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   NATCO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  DIVIS LABORATORIES  FULFORD INDIA  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Trade War Fears; Widening of Trade Deficit and Top Stocks in Action Today(Pre-Open)

Indian share markets trimmed their day's losses and ended flat on Friday amid weakness in their Asian peers, that wobbled on Friday as investors braced for US tariffs against China.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jun 15, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - SUVEN LIFE COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS